Squarepoint’s Sarepta Therapeutics SRPT Stock Holding History

Squarepoint’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,500	Closed	-$359K	–	4952
2026 Q1	$359K	Sell	16,500 -39,000	-70%	-$755K	﹤0.01%	3568
2025 Q4	$1.19M	Sell	55,500 -57,000	-51%	-$1.2M	﹤0.01%	2458
2025 Q3	$2.17M	Buy	112,500 +84,700	+305%	+$1.51M	﹤0.01%	2029
2025 Q2	$475K	Buy	27,800 +3,800	+16%	+$162K	﹤0.01%	3321
2025 Q1	$1.53M	Sell	24,000 -12,400	-34%	-$1.31M	﹤0.01%	2305
2024 Q4	$4.43M	Buy	36,400 +34,000	+1,417%	+$4.17M	﹤0.01%	1741
2024 Q3	$300K	Buy	+2,400	New	+$332K	﹤0.01%	3446

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Squarepoint's SRPT Position: Q2 2026 in Review

Squarepoint reduced its Sarepta Therapeutics (SRPT) stake by 44% in Q2 2026, selling an estimated $1.23M and leaving 84,026 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

Squarepoint first reported a position in SRPT in Q4 2016 and has held it in 33 quarters since. The position peaked at $26.8M in Q4 2022. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Squarepoint held 84,026 shares of Sarepta Therapeutics worth $1.51M as of Q2 2026.
Squarepoint sold 64,776 Sarepta Therapeutics shares in Q2 2026, an estimated $1.23M.
Sarepta Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2557 holding.
Squarepoint first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 33 quarters since.
Squarepoint's Sarepta Therapeutics position peaked at $26.8M in Q4 2022.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.